drugset / Trial / NCT00656617
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS. Once the highest safe dose is found, researchers will then try to learn if this combination treatment can help to control AML and high-risk MDS in newly diagnosed patients. The safety of this treatment combination will also be studied.
Timeline
- Start
- 2008-04
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 1500 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Vorinostat | Small molecule | 500 mg | Oral |